This article reviews the unique toxicities and adverse effects of blinatumomab and inotuzumab ozogamicin and provide recommendations for prevention of adverse effects as well as the management options for each medication.
This study evaluates the impact of cutaneous adverse events on quality of life in outpatients receiving anticancer drugs and aims to determine the differences in quality of life between conventional chemotherapy versus targeted therapies.
This study aims to (1) provide an estimate for the prevalence of treated mycosis fungoides-type cutaneous T-cell lymphoma (MF-CTCL) patients in Spain, (2) describe the Spanish patient treatment pathways for MF-CTCL, including quantification of the distribution of patients between primary, secondary and tertiary care institutions, and (3) investigate and quantify the treatment preferences of physicians.
The aim of this paper is to discuss current knowledge on radiation-induced dermatitis and propose targets for the prevention/treatment of this
condition. On these bases, the characteristics of the ‘ideal’
compound to address this side effect will be described.
